NCT03064490View on ClinicalTrials.gov

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

February 24, 2023

Study Completion Date

November 22, 2023

Conditions
Locally Advanced Esophageal and Gastric Cancers (EGC)
Interventions
DRUG

Pembrolizumab

Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)

Trial Locations (1)

27710

Duke Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER